On April 29, 2025, Entrada Therapeutics, Inc. announced a new strategic plan to enhance focus on its clinical candidates for Duchenne muscular dystrophy (DMD) while reducing its workforce by about 20%, incurring costs of approximately $2 million related to the layoffs.